ES2589459T3 - Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevención de una enfermedad viral - Google Patents

Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevención de una enfermedad viral Download PDF

Info

Publication number
ES2589459T3
ES2589459T3 ES12787384.2T ES12787384T ES2589459T3 ES 2589459 T3 ES2589459 T3 ES 2589459T3 ES 12787384 T ES12787384 T ES 12787384T ES 2589459 T3 ES2589459 T3 ES 2589459T3
Authority
ES
Spain
Prior art keywords
alkyl
compound
aryl
cycloalkyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12787384.2T
Other languages
English (en)
Spanish (es)
Inventor
Dirk Classen-Houben
Andrea Wolkerstorfer
Oliver Szolar
Mark Smith
Sung-Sau So
Stephen Cusack
Thierry Langer
Bruno Giethlen
Christophe Morice
Céline MICHAUT-SIMON
Laurence JUNG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savira Pharmaceuticals GmbH
F Hoffmann La Roche AG
European Molecular Biology Laboratory
Original Assignee
Savira Pharmaceuticals GmbH
F Hoffmann La Roche AG
European Molecular Biology Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savira Pharmaceuticals GmbH, F Hoffmann La Roche AG, European Molecular Biology Laboratory filed Critical Savira Pharmaceuticals GmbH
Application granted granted Critical
Publication of ES2589459T3 publication Critical patent/ES2589459T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES12787384.2T 2011-10-21 2012-10-19 Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevención de una enfermedad viral Active ES2589459T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550057P 2011-10-21 2011-10-21
US201161550057P 2011-10-21
PCT/EP2012/070760 WO2013057253A1 (en) 2011-10-21 2012-10-19 Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease

Publications (1)

Publication Number Publication Date
ES2589459T3 true ES2589459T3 (es) 2016-11-14

Family

ID=47189887

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12787384.2T Active ES2589459T3 (es) 2011-10-21 2012-10-19 Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevención de una enfermedad viral

Country Status (11)

Country Link
US (2) US20130102601A1 (enExample)
EP (1) EP2794616B1 (enExample)
JP (1) JP6033873B2 (enExample)
KR (1) KR20140097197A (enExample)
CN (1) CN103958521B (enExample)
BR (1) BR112014008412A2 (enExample)
CA (1) CA2852843A1 (enExample)
ES (1) ES2589459T3 (enExample)
MX (1) MX342176B (enExample)
RU (1) RU2014120477A (enExample)
WO (1) WO2013057253A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2953862A1 (en) 2014-07-07 2016-01-14 F. Hoffmann-La Roche Ag Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases
AU2015306643B2 (en) * 2014-08-28 2020-05-07 X-Chem, Inc. Soluble epoxide hydrolase inhibitors and uses thereof
WO2016133888A1 (en) * 2015-02-16 2016-08-25 Biota Pharmaceuticals, Inc. Compounds for treating respiratory syncytial virus infections
CN107709321A (zh) 2015-04-28 2018-02-16 盐野义制药株式会社 经取代的多环性吡啶酮衍生物及其前药
US20170081331A1 (en) 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
HK1254961A1 (en) 2015-12-15 2019-08-02 Shionogi & Co., Ltd. Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
JP6957535B2 (ja) 2016-06-29 2021-11-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ピリダジノンベースの広域スペクトル抗インフルエンザ阻害剤
US10759814B2 (en) 2016-08-10 2020-09-01 Shionogi & Co., Ltd. Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
CN111032646B (zh) 2017-08-01 2023-01-03 施万生物制药研发Ip有限责任公司 作为jak激酶抑制剂的吡唑并和三唑并双环化合物
CN113498352A (zh) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
MX2022012677A (es) * 2020-04-08 2023-01-11 Remix Therapeutics Inc Compuestos y metodos para modular el empalme.
EP4308572B1 (en) * 2021-03-17 2025-04-23 F. Hoffmann-La Roche AG New thienopyrimidinone derivatives
US11932656B1 (en) 2023-10-06 2024-03-19 King Faisal University Thieno[2,3-d]pyrimidines as COX-2 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
KR100714519B1 (ko) * 2002-03-07 2007-05-07 에프. 호프만-라 로슈 아게 이환 피리딘 및 피리미딘 ｐ38 키나아제 억제제
JP4953297B2 (ja) 2004-09-15 2012-06-13 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体
SI2215094T1 (sl) * 2007-11-15 2016-05-31 Ym Biosciences Australia Pty Ltd N vsebujoče heterociklične spojine
EP2923734B1 (en) 2009-03-13 2018-01-10 Katholieke Universiteit Leuven, K.U. Leuven R&D Purine analogues and their use as immunosuppressive agents
US8835461B2 (en) 2009-03-26 2014-09-16 Shionogi & Co., Ltd. Substituted 3-hydroxy-4-pyridone derivative
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
WO2011000566A2 (en) * 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections

Also Published As

Publication number Publication date
MX2014003801A (es) 2015-03-11
MX342176B (es) 2016-09-20
HK1199881A1 (en) 2015-07-24
JP6033873B2 (ja) 2016-11-30
KR20140097197A (ko) 2014-08-06
CN103958521B (zh) 2016-10-19
EP2794616A1 (en) 2014-10-29
US20160376286A1 (en) 2016-12-29
CN103958521A (zh) 2014-07-30
EP2794616B1 (en) 2016-06-29
WO2013057253A1 (en) 2013-04-25
US20130102601A1 (en) 2013-04-25
JP2014530838A (ja) 2014-11-20
CA2852843A1 (en) 2013-04-25
BR112014008412A2 (pt) 2017-04-11
RU2014120477A (ru) 2015-11-27

Similar Documents

Publication Publication Date Title
EP2794616B1 (en) Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
US8921388B2 (en) Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
CN103958475B (zh) 杂芳基异羟肟酸衍生物及其在治疗、减轻或预防病毒疾病中的用途
EP2864338B1 (en) 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
EP2861232A1 (en) 7-oxo-4,7 -dihydro- pyrazolo [1, 5 -a]pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease
CA2894452A1 (en) Pyridone derivatives and their use in the treatment, amelioration or prevention of a viral disease
ES2935615T3 (es) Azetidina dihidrotienopiridinas sustituidas y su uso como inhibidores de la fosfodiesterasa
WO2017046318A1 (en) Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease
ES2597803T3 (es) Derivados de naftiridinona y su uso en el tratamiento, mejora o prevención de una enfermedad viral
HK1199881B (en) Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
HK1205128B (en) 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease